Advertisement

Fabry Disease pp 211-243 | Cite as

Renal Manifestations of Fabry Disease

  • David G. WarnockEmail author
  • Carmen Valbuena
  • Michael West
  • João Paulo Oliveira
Chapter

Abstract

The majority of Fabry patients have kidney involvement (nephropathy), with significant proteinuria and progressive loss of kidney function leading to end-stage-renal-disease. Baseline assessment of the severity of Fabry nephropathy, institution of appropriate therapy, and close monitoring of the subsequent course is essential. Once present, target kidney damage is not reversed, so stopping further progression is the treatment goal. Fabry nephropathy is treatable, even in patients with fairly advanced disease. While the cornerstone of therapy remains enzyme replacement therapy with agalsidase preparations, this treatment alone does not reduce urine protein excretion. Treatment with angiotensin converting enzyme inhibitors or angiotensin receptor blockers must be added to enzyme replacement therapy to reduce urine protein excretion with the goal that this will stabilize kidney function. Kidney function, with estimated glomerular filtration rate based on serum creatinine, and measurements of urinary protein should be obtained at every clinic visit, and the rate of loss of function followed over time. Anti-proteinuric therapy can be dosed to a pre-specified urine protein target rather than a specific blood pressure goal, recognizing that successful therapy will usually lower the blood pressure below the goal of 130/80 mmHg used for other forms of kidney disease. The overall goal for treating Fabry nephropathy is to reduce the rate of loss of glomerular filtration rate to ≤ −1.0 ml/min/1.73 m2/year, which is that seen in the normal adult population.

Keywords

Chronic kidney disease Focal glomerular sclerosis Glomerular filtration rate Proteinuria Renal biopsy 

Abbreviations

ACEI

Angiotensin converting enzyme inhibitor

ARB

Angiotensin receptor blocker

CKD

Chronic kidney disease

eGFR

Estimated GFR

EM

Electron microscopy

ESRD

End-stage renal disease

ERT

Enzyme replacement therapy

GFR

Glomerular filtration rate

GLA

The α-galactosidase A locus

GL-3

Globotriaosylceramide

mGFR

Measured GFR

References

  1. 1.
    Desnick RJ, Ioannou YA, Eng CM (2001) Alpha-Galactosidase A deficiency: Fabry disease. In: Scriver C, Beaudet A, Sly W, Valle D (eds) The metabolic bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3733–3774Google Scholar
  2. 2.
    Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G et al (2002) Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 81(2):122–138CrossRefGoogle Scholar
  3. 3.
    Mehta A, Ricci R, Widmer U, Dehout F, Garcia de Lorenzo A, Kampmann C et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34(3):236–242PubMedCrossRefGoogle Scholar
  4. 4.
    Deegan PB, Baehner AF, Barba Romero MA, Hughes DA, Kampmann C, Beck M (2006) Natural history of Fabry disease in females in the Fabry Outcome Survey. J Med Genet 43(4):347–352PubMedCrossRefGoogle Scholar
  5. 5.
    Ortiz A, Oliveira JP, Waldek S, Warnock DG, Cianciaruso B, Wanner C (2008) Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant 9(23):1600–1607CrossRefGoogle Scholar
  6. 6.
    Wilcox WR, Oliveira JP, Hopkin RJ, Ortiz A, Banikazemi M, Feldt-Rasmussen U et al (2008) Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. Mol Genet Metab 93(2):112–128PubMedCrossRefGoogle Scholar
  7. 7.
    Kobayashi M, Ohashi T, Sakuma M, Ida H, Eto Y (2008) Clinical manifestations and natural history of Japanese heterozygous females with Fabry disease. J Inherit Metab Dis online report #003 DOI 10.1007/s10545-007-0740–6Google Scholar
  8. 8.
    Schiffmann R, Warnock DG, Banikazemi M, Bultas J, Linthorst GE, Packman S et al (2009) Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant 24(7):2102–2111PubMedCrossRefGoogle Scholar
  9. 9.
    Oqvist B, Brenner BM, Oliveira JP, Ortiz A, Schaefer R, Svarstad E et al (2009) Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations. Nephrol Dial Transplant 24(6):1736–1743PubMedCrossRefGoogle Scholar
  10. 10.
    Pompen AW, Ruiter M, Wyers HJ (1947) Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports. Acta Med Scand 128(3):234–255PubMedCrossRefGoogle Scholar
  11. 11.
    Scriba K (1950) Zur Pathogenese des Angiokeratoma corporis diffusum Fabry mit cardio vasorenalem symptomenkomplex [Article in German]. Verhandlg Deutsch Path Gesellsch 34:221–226Google Scholar
  12. 12.
    Hornbostel H, Spier W, Koch H (1951) Angiokeratoma corporis diffusum universale (Fabry) with cardio-vaso-renal symptom complex as general disease (Article in German). Arztl Wochensch 6(3):49–55PubMedGoogle Scholar
  13. 13.
    Karr WJ Jr. (1959) Fabry’s disease (angiokeratoma corporis diffusum universale). An unusual syndrome with multisystem involvement and unique skin manifestations. Am J Med 27:829–835PubMedCrossRefGoogle Scholar
  14. 14.
    Wise D, Wallace HJ, Jellinek EH (1962) Angiokeratoma corporis diffusum. A clinical study of eight affected families. Q J Med 31:177–206PubMedGoogle Scholar
  15. 15.
    De Groot WP (1968) Angiokeratoma corporis diffusum Fabry. Dermatologica 136(5):432–433PubMedCrossRefGoogle Scholar
  16. 16.
    Colley JR, Miller DL, Hutt MS, Wallace HJ, De Wardener HE (1958) The renal lesion in angiokeratoma corporis diffusum. Br Med J 1(5082):1266–1268PubMedCrossRefGoogle Scholar
  17. 17.
    Rahman AN, Simeone FA, Hackel DB, Hall PW III, Hirsch EZ, Harris JW (1961) Angokeratoma corporis diffusum universale (hereditary dystropic lipidosis). Trans Am Assoc Physicians 74:366–377Google Scholar
  18. 18.
    De Groot WP (1964) Angiokeratoma corporis diffusum Fabry. Dermatologica 128:321–349CrossRefGoogle Scholar
  19. 19.
    Burda CD, Winder PR (1967) Angiokeratoma corporis diffusum universale (Fabry’s disease) in female subjects. Am J Med 42(2):293–301PubMedCrossRefGoogle Scholar
  20. 20.
    Clarke JT, Knaack J, Crawhall JC, Wolfe LS (1971) Ceramide trihexosidosis (Fabry’s disease) without skin lesions. N Engl J Med 284(5):233–235PubMedCrossRefGoogle Scholar
  21. 21.
    Kitagawa T, Suzuki K, Ishige N, Ohashi T, Kobayashi M, Eto Y et al (2008) Non-invasive high-risk screening for Fabry disease hemizygotes and heterozygotes. Pediatr Nephrol 23(9):1461–1471PubMedCrossRefGoogle Scholar
  22. 22.
    Ortiz A, Oliveira JP, Wanner C, Brenner BM, Waldek S, Warnock DG (2008) Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol 4(6):327–336PubMedCrossRefGoogle Scholar
  23. 23.
    Zarate YA, Patterson L, Yin H, Hopkin RJ (2009) A case of minimal change disease in a Fabry patient. Pediatr Nephrol 25(3):553–556PubMedCrossRefGoogle Scholar
  24. 24.
    Kawamura O, Sakuraba H, Itoh K, Suzuki Y, Doi M, Kuwabara H et al (1997) Subclinical Fabry’s disease occurring in the context of IgA nephropathy. Clin Nephrol 47(2):71–75PubMedGoogle Scholar
  25. 25.
    Pisani A, Sessa A, Sabbatini M, Andreucci MV, Fusco C, Balletta M et al (2005) Fabry nephropathy in a female with superposed IgA glomerulonephritis [in Italian]. G Ital Nefrol 22(4):385–389PubMedGoogle Scholar
  26. 26.
    Whybra C, Schwarting A, Kriegsmann J, Gal A, Mengel E, Kampmann C et al (2006) IgA nephropathy in two adolescent sisters heterozygous for Fabry disease. Pediatr Nephrol 21(9):1251–1256PubMedCrossRefGoogle Scholar
  27. 27.
    Valbuena C, Carvalho E, Bustorff M, Ganhão M, Relvas S, Nogueira R et al (2008) Kidney biospy findings in heterozygous Fabry disease females with early nephropathy. Virchows Arch 453(4):329–338PubMedCrossRefGoogle Scholar
  28. 28.
    Singh HK, Nickeleit V, Kriegsmann J, Harris AA, Jennette JC, Mihatsch MJ (2001) Coexistence of Fabry’s disease and necrotizing and crescentic glomerulonephritis. Clin Nephrol 55(1):73–79PubMedGoogle Scholar
  29. 29.
    Shimazu K, Tomiyoshi Y, Aoki S, Sakemi T, Sugihara H (2002) Crescentic glomerulonephritis in a patient with heterozygous Fabry’s disease. Nephron 92(2):456–458PubMedCrossRefGoogle Scholar
  30. 30.
    Kriegsmann J, Otto M, Wandel E, Schwarting A, Faust J, Hansen T et al (2003) Fabry’s disease, glomerulonephritis with crescentic and granulomatous interstitial nephritis. Case of one family [in German]. Pathologe 24(6):439–443PubMedCrossRefGoogle Scholar
  31. 31.
    Rosenmann E, Kobrin I, Cohen T (1983) Kidney involvement in systemic lupus erythematosus and Fabry’s disease. Nephron 34(3):180–184PubMedCrossRefGoogle Scholar
  32. 32.
    Majima K, Ishizaki T, Inoue T, Hori Y, Egami J, Oohara A et al (1992) A case of Fabry’s disease associated with lupus nephritis [in Japenese]. Nippon Jinzo Gakkai Shi 34(11):1189–1194PubMedGoogle Scholar
  33. 33.
    Ries M, Bettis KE, Choyke P, Kopp JB, Austin HA III, Brady RO et al (2004) Parapelvic kidney cysts: a distinguishing feature with high prevalence in Fabry disease. Kidney Int 66(3):978–982PubMedCrossRefGoogle Scholar
  34. 34.
    Banks DE, Milutinovic J, Desnick RJ, Grabowski GA, Lapp NL, Boehlecke BA (1983) Silicon nephropathy mimicking Fabry’s disease. Am J Nephrol 3(5):279–284PubMedCrossRefGoogle Scholar
  35. 35.
    Woywodt A, Hellweg S, Schwarz A, Schaefer RM, Mengel M (2007) A wild zebra chase. Nephrol Dial Transplant 22(10):3074–3077PubMedCrossRefGoogle Scholar
  36. 36.
    Muller-Hocker J, Schmid H, Weiss M, Dendorfer U, Braun GS (2003) Chloroquine-induced phospholipidosis of the kidney mimicking Fabry’s disease: case report and review of the literature. Hum Pathol 34(3):285–289PubMedCrossRefGoogle Scholar
  37. 37.
    Albay D, Adler SG, Philipose J, Calescibetta CC, Romansky SG, Cohen AH (2005) Chloroquine-induced lipidosis mimicking Fabry disease. Mod Pathol 18(5):733–738PubMedCrossRefGoogle Scholar
  38. 38.
    Bracamonte ER, Kowalewska J, Starr J, Gitomer J, Alpers CE (2006) Iatrogenic phospholipidosis mimicking Fabry disease. Am J Kidney Dis 48(5):844–850PubMedCrossRefGoogle Scholar
  39. 39.
    Houghton DC, Campbell-Boswell MV, Bennett WM, Porter GA, Brooks RE (1978) Myeloid bodies in the renal tubules of humans: relationship to gentamicin therapy. Clin Nephrol 10(4):140–145PubMedGoogle Scholar
  40. 40.
    Ferreira S, Valbuena C, Carvalho F, Oliveira JP (2009) Novel human pathological mutations. Gene symbol: GLA. Disease: Fabry disease. Hum Genet 126(2):352PubMedGoogle Scholar
  41. 41.
    Desnick RJ, Banikazemi M, Wasserstein M (2002) Enzyme replacement therapy for Fabry disease, an inherited nephropathy. Clin Nephrol 57(1):1–8PubMedGoogle Scholar
  42. 42.
    Chatterjee S, Gupta P, Pyeritz RE, Kwiterovich PO Jr. (1984) Immunohistochemical localization of glycosphingolipid in urinary renal tubular cells in Fabry’s disease. Am J Clin Pathol 82(1):24–28PubMedGoogle Scholar
  43. 43.
    Henry EW, Rally CR (1963) The renal lesion in angiokeratoma corporis diffusum (Fabry’s disease). Can Med Assoc J 3(89):206–213Google Scholar
  44. 44.
    Pabico RC, Atancio BC, McKenna BA, Pamukcoglu T, Yodaiken R (1973) Renal pathologic lesions and functional alterations in a man with Fabry’s disease. Am J Med 55(3):415–425PubMedCrossRefGoogle Scholar
  45. 45.
    Wornell P, Dyack S, Crocker J, Yu W, Accott P (2006) Fabry disease and nephrogenic diabetes insipidus. Pediatr Nephrol 21:1185–1188PubMedCrossRefGoogle Scholar
  46. 46.
    Sessa A, Meroni M, Battini G, Righetti M, Maglio A, Tosoni A et al (2003) Renal involvement in Anderson-Fabry disease. J Nephrol 16(2):310–313PubMedGoogle Scholar
  47. 47.
    Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ et al (2005) Pediatric Fabry disease. Pediatrics 115(3):344–355CrossRefGoogle Scholar
  48. 48.
    Ramaswami U, Whybra C, Parini R, Pintos-Morell G, Mehta A, Sunder-Plassmann G et al (2006) Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr 95(1):86–92PubMedCrossRefGoogle Scholar
  49. 49.
    Hopkin RJ, Bissler J, Banikazemi M, Clarke L, Eng CM, Germain DP et al (2008) Characterization of Fabry disease in 352 pediatric patients in the Fabry Registry. Pediatr Res 64(5):550–555PubMedCrossRefGoogle Scholar
  50. 50.
    Branton M, Schiffmann R, Kopp JB (2002) Natural history and treatment of renal involvement in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S139–S143PubMedGoogle Scholar
  51. 51.
    Ries M, Ramaswami U, Parini R, Lindblad B, Whybra C, Willers I et al (2003) The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162(11):767–772PubMedCrossRefGoogle Scholar
  52. 52.
    Sheth KJ, Roth DA, Adams MB (1983) Early renal failure in Fabry’s disease. Am J Kidney Dis 2(6):651–654PubMedGoogle Scholar
  53. 53.
    Levey AS, Stevens LA, Schmid CH, Zhang Y, Castro AF III, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604–612PubMedGoogle Scholar
  54. 54.
    Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C et al (2005) Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey. Kidney Int 67(5):1955–1960PubMedCrossRefGoogle Scholar
  55. 55.
    Oliveira JP, Valbuena C, Baldaia Moreira A, Fonseca E, Soares C, Leao Teles E et al (2008) Splenomegaly, hypersplenism and peripheral blood cytopaenias in patients with classical Anderson-Fabry disease. Virchows Arch 453(3):291–300PubMedCrossRefGoogle Scholar
  56. 56.
    Rodriguez-Iturbe B, Herrera J, Garcia R (1985) Response to acute protein load in kidney donors and in apparently normal postacute glomerulonephritis patients: evidence for glomerular hyperfiltration. Lancet 2(8453):461–464PubMedCrossRefGoogle Scholar
  57. 57.
    West M, Nicholls K, Mehta A, Clarke JT, Steiner R, Beck M et al (2009) Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 20(5):1132–1139PubMedCrossRefGoogle Scholar
  58. 58.
    Schwartz GJ, Haycock GB, Edelmann CM Jr., Spitzer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58(2):259–263PubMedGoogle Scholar
  59. 59.
    Tondel C, Bostad L, Hirth A, Svarstad E (2008) Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Am J Kidney Dis 51(5):767–776PubMedCrossRefGoogle Scholar
  60. 60.
    Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function–measured and estimated glomerular filtration rate. N Engl J Med 354(23):2473–2483PubMedCrossRefGoogle Scholar
  61. 61.
    Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476):307–310PubMedCrossRefGoogle Scholar
  62. 62.
    Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA et al (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20(3):629–637PubMedCrossRefGoogle Scholar
  63. 63.
    Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM (1976) Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 51(11):875–878PubMedCrossRefGoogle Scholar
  64. 64.
    Ries M, Clarke JT, Whybra C, Timmons M, Robinson C, Schlaggar BL et al (2006) Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics 118(3):924–932PubMedCrossRefGoogle Scholar
  65. 65.
    Kleinert J, Dehout F, Schwarting A, de Lorenzo AG, Ricci R, Kampmann C et al (2006) Prevalence of uncontrolled hypertension in patients with Fabry disease. Am J Hypertens 19(8):782–787PubMedCrossRefGoogle Scholar
  66. 66.
    Glass RB, Astrin KH, Norton KI, Parsons R, Eng CM, Banikazemi M et al (2004) Fabry disease: renal sonographic and magnetic resonance imaging findings in affected males and carrier females with the classic and cardiac variant phenotypes. J Comput Assist Tomogr 28(2):158–168PubMedCrossRefGoogle Scholar
  67. 67.
    Donati D, Novario R, Gastaldi L (1987) Natural history and treatment of uremia secondary to Fabry’s disease: an European experience. Nephron 46(4):353–359PubMedCrossRefGoogle Scholar
  68. 68.
    Colombi A, Kostyal A, Bracher R, Gloor F, Mazzi R, Tholen H (1967) Angiokeratoma corporis diffusum–Fabry’s disease. Helv Med Acta 34(1):67–83PubMedGoogle Scholar
  69. 69.
    MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38(11):750–760PubMedCrossRefGoogle Scholar
  70. 70.
    Shah T, Gill J, Malhotra N, Takemoto SK, Bunnapradist S (2009) Kidney transplant outcomes in patients with Fabry disease. Transplantation 87(2):280–285PubMedCrossRefGoogle Scholar
  71. 71.
    Tsakiris D, Simpson HK, Jones EH, Briggs JD, Elinder CG, Mendel S et al (1996) Report on management of renale failure in Europe, XXVI, 1995. Rare diseases in renal replacement therapy in the ERA-EDTA Registry. Nephrol Dial Transplant 11(Suppl 7):4–20PubMedCrossRefGoogle Scholar
  72. 72.
    Thadhani R, Wolf M, West ML, Tonelli M, Ruthazer R, Pastores GM et al (2002) Patients with Fabry disease on dialysis in the United States. Kidney Int 61(1):249–255PubMedCrossRefGoogle Scholar
  73. 73.
    Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281(3):249–254PubMedCrossRefGoogle Scholar
  74. 74.
    Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105(1–2):151–156PubMedGoogle Scholar
  75. 75.
    Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman A et al (2000) Excellent outcome of renal transplantation in patients with Fabry’s disease. Transplantation 69(11):2337–2339PubMedCrossRefGoogle Scholar
  76. 76.
    Sessa A, Meroni M, Battini G, Righetti M, Mignani R (2004) Chronic renal failure, dialysis, and renal transplantation in Anderson-Fabry disease. Semin Nephrol 24(5):532–536PubMedCrossRefGoogle Scholar
  77. 77.
    Garman SC, Garboczi DN (2004) The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. J Mol Biol 337(2):319–335PubMedCrossRefGoogle Scholar
  78. 78.
    Matsuzawa F, Aikawa SI, Doi H, Okumiya T, Sakuraba H (2005) Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes. Hum Genet 117(4):317–328PubMedCrossRefGoogle Scholar
  79. 79.
    Desnick RJ, Allen KY, Desnick SJ, Raman MK, Bernlohr RW, Krivit W (1973) Fabry’s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 81(2):157–171PubMedGoogle Scholar
  80. 80.
    Nakao S, Kodama C, Takenaka T, Tanaka A, Yasumoto Y, Yoshida A et al (2003) Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a ‘renal variant’ phenotype. Kidney Int 64(3):801–807PubMedCrossRefGoogle Scholar
  81. 81.
    Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M et al (2004) Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 15(5):1323–1329PubMedCrossRefGoogle Scholar
  82. 82.
    Kleinert J, Kotanko P, Spada M, Pagliardini S, Paschke E, Paul K et al (2009) Anderson-Fabry disease: a case-finding study among male kidney transplant recipients in Austria. Transpl Int 22(3):287–292PubMedCrossRefGoogle Scholar
  83. 83.
    Merta M, Reiterova J, Ledvinova J, Poupetova H, Dobrovolny R, Rysava R et al (2007) A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant 22(1):179–186PubMedCrossRefGoogle Scholar
  84. 84.
    Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H et al (2006) High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31–40PubMedCrossRefGoogle Scholar
  85. 85.
    Utsumi K, Kase R, Takata T, Sakuraba H, Matsui N, Saito H et al (2000) Fabry disease in patients receiving maintenance dialysis. Clin Exp Nephrol 4(1):46–51CrossRefGoogle Scholar
  86. 86.
    Ichinose M, Nakayama M, Ohashi T, Utsunomiya Y, Kobayashi M, Eto Y (2005) Significance of screening for Fabry disease among male dialysis patients. Clin Exp Nephrol 9(3):228–232PubMedCrossRefGoogle Scholar
  87. 87.
    Tanaka M, Ohashi T, Kobayashi M, Eto Y, Miyamura N, Nishida K et al (2005) Identification of Fabry’s disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol 64(4):281–287PubMedGoogle Scholar
  88. 88.
    Andrade J, Waters PJ, Singh RS, Levin A, Toh BC, Vallance HD et al (2008) Screening for Fabry disease in patients with chronic kidney disease: limitations of plasma alpha-galactosidase assay as a screening test. Clin J Am Soc Nephrol 3(1):139–145PubMedCrossRefGoogle Scholar
  89. 89.
    Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M et al (1995) An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med 333(5):288–293PubMedCrossRefGoogle Scholar
  90. 90.
    Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ et al (2002) Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 105(12):1407–1411PubMedCrossRefGoogle Scholar
  91. 91.
    Yoshitama T, Nakao S, Takenaka T, Teraguchi H, Sasaki T, Kodama C et al (2001) Molecular genetic, biochemical, and clinical studies in three families with cardiac Fabry’s disease. Am J Cardiol 87(1):71–75PubMedCrossRefGoogle Scholar
  92. 92.
    Altarescu G, Elstein D (2005) Cardiac abnormalities in Fabry disease: natural history in hemizygote males suggests that cardiac pathology is universally present. Haema 8(1):103–108Google Scholar
  93. 93.
    Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y et al (2008) Terminal stage cardiac findings in patients with cardiac Fabry disease: An electrocardiographic, echocardiographic, and autopsy study. J Cardiol 51(1):50–59PubMedCrossRefGoogle Scholar
  94. 94.
    Sweeley CC, Klionsky B (1963) Fabry’s disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 238:3148–3150PubMedGoogle Scholar
  95. 95.
    Schibanoff JM, Kamoshita S, O’Brien JS (1969) Tissue distribution of glycosphingolipids in a case of Fabry’s disease. J Lipid Res 10(5):515–520PubMedGoogle Scholar
  96. 96.
    Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R (1978) Early renal changes in hemizygous and heterozygous patients with Fabry’s disease. Kidney Int 13(3):223–235PubMedCrossRefGoogle Scholar
  97. 97.
    Sessa A, Toson A, Nebuloni M, Pallotti F, Giordano F, Battini G et al (2002) Renal ultrastructural findings in Anderson-Fabry disease. J Nephrol 15(2):109–112PubMedGoogle Scholar
  98. 98.
    Elleder M, Poupetova H, Kozich V (1998) Fetal pathology in Fabry’s disease and mucopolysaccharidosis type I [in Czech]. Cesk Patol 34(1):7–12PubMedGoogle Scholar
  99. 99.
    Mårtensson E (1966) Neutral glycolipids of human kidney isolation, identification, and fatty acid composition. Biochim Biophys Acta 116(2):296–308PubMedCrossRefGoogle Scholar
  100. 100.
    Makita A, Iwanaga M, Yamakawa T (1964) The chemical structure of human kidney globoside. J Biochem 55:202–204PubMedGoogle Scholar
  101. 101.
    Kojima Y, Fukumoto S, Furukawa K, Okajima T, Wiels J, Yokoyama K et al (2000) Molecular cloning of globotriaosylceramide/CD77 synthase, a glycosyltransferase that initiates the synthesis of globo series glycosphingolipids. J Biol Chem 275(20):15152–15156PubMedCrossRefGoogle Scholar
  102. 102.
    Abe A, Gregory S, Lee L, Killen PD, Brady RO, Kulkarni A et al (2000) Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation. J Clin Invest 105(11):1563–1571PubMedCrossRefGoogle Scholar
  103. 103.
    Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M et al (2000) Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355(9214):1481–1485PubMedCrossRefGoogle Scholar
  104. 104.
    Cohen A, Hannigan GE, Williams BR, Lingwood CA (1987) Roles of globotriosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J Biol Chem 262(35):17088–17091PubMedGoogle Scholar
  105. 105.
    Ergonul Z, Clayton F, Fogo AB, Kohan DE (2003) Shigatoxin-1 binding and receptor expression in human kidneys do not change with age. Pediatr Nephrol 18(3):246–253PubMedGoogle Scholar
  106. 106.
    Meyers KE, Kaplan BS (2000) Many cell types are Shiga toxin targets. Kidney Int 57(6):2650–2651PubMedCrossRefGoogle Scholar
  107. 107.
    Thomaidis T, Relle M, Golbas M, Brochhausen C, Galle PR, Beck M et al (2009) Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy. Kidney Int 75(4):399–407PubMedCrossRefGoogle Scholar
  108. 108.
    Mills K, Johnson A, Winchester B (2002) Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry. FEBS Lett 515(1–3):171–176PubMedCrossRefGoogle Scholar
  109. 109.
    Fuller M, Sharp PC, Rozaklis T, Whitfield PD, Blacklock D, Hopwood JJ et al (2005) Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes. Clin Chem 51(4):688–694PubMedCrossRefGoogle Scholar
  110. 110.
    Grunfeld JP, Le Porrier M, Droz D, Bensaude I, Hinglais N, Crosnier J (1975) La transplantation rénale chez les sujets atteints de maladie de Fabry. Transplantation du rein d’un sujet hétérozygote à un sujet sain [in French]. Nouv Presse Med 4(29):2081–2085PubMedGoogle Scholar
  111. 111.
    Sessa A, Meroni M, Battini G, Maglio A, Brambilla PL, Bertella M et al (2001) Renal pathological changes in Fabry disease. J Inherit Metab Dis 24(Suppl 2):66–70, discussion 65PubMedCrossRefGoogle Scholar
  112. 112.
    Alroy J, Sabnis S, Kopp JB (2002) Renal pathology in Fabry disease. J Am Soc Nephrol 13(Suppl 2):S134–S138PubMedGoogle Scholar
  113. 113.
    Fischer EG, Moore MJ, Lager DJ (2006) Fabry disease: a morphologic study of 11 cases. Mod Pathol 19(10):1295–1301PubMedCrossRefGoogle Scholar
  114. 114.
    Burkholder PM, Updike SJ, Ware RA, Reese OG (1980) Clinicopathologic, enzymatic, and genetic features in a case of Fabry’s disease. Arch Pathol Lab Med 104(1):17–25PubMedGoogle Scholar
  115. 115.
    Faraggiana T, Churg J, Grishman E, Strauss L, Prado A, Bishop DF et al (1981) Light- and electron-microscopic histochemistry of Fabry’s disease. Am J Pathol 103(2):247–262PubMedGoogle Scholar
  116. 116.
    Fukushima M, Tsuchiyama Y, Nakato T, Yokoi T, Ikeda H, Yoshida S et al (1995) A female heterozygous patient with Fabry’s disease with renal accumulation of trihexosylceramide detected with a monoclonal antibody. Am J Kidney Dis 26(6):952–955PubMedCrossRefGoogle Scholar
  117. 117.
    Askari H, Kaneski CR, Semino-Mora C, Desai P, Ang A, Kleiner DE et al (2007) Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch 451(4):823–834PubMedCrossRefGoogle Scholar
  118. 118.
    Kotani M, Kawashima I, Ozawa H, Ogura K, Ariga T, Tai T (1994) Generation of one set of murine monoclonal antibodies specific for globo-series glycolipids: evidence for differential distribution of the glycolipids in rat small intestine. Arch Biochem Biophys 310(1):89–96PubMedCrossRefGoogle Scholar
  119. 119.
    Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB et al (2002) Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62(6):1933–1946PubMedCrossRefGoogle Scholar
  120. 120.
    Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F et al (2010) Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant 25 (in press)Google Scholar
  121. 121.
    Tosoni A, Nebuloni M, Zerbi P, Vago L, Comotti C, Sessa A (2005) Ultrastructural study of renal involvement in two females with Anderson-Fabry disease. Ultrastruct Pathol 29(3–4):203–207PubMedCrossRefGoogle Scholar
  122. 122.
    Faria V (1970) Fabry disease, a rare thesausrismosis [in Portugese]. Jornal do Médico. [Case report] 72(1423):5–11Google Scholar
  123. 123.
    Oliveira JP (2007) Staging of Fabry disease using renal biopsies. Clin Therap 29(Suppl A):SGoogle Scholar
  124. 124.
    Meehan SM, Junsanto T, Rydel JJ, Desnick RJ (2004) Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications. Am J Kidney Dis 43(1):164–171PubMedCrossRefGoogle Scholar
  125. 125.
    Warnock DG (2005) Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr Opin Nephrol Hypertens 14(2):87–95PubMedCrossRefGoogle Scholar
  126. 126.
    Remuzzi G, Benigni A, Remuzzi A (2006) Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 116(2):288–296PubMedCrossRefGoogle Scholar
  127. 127.
    Ruggenenti P, Perna A, Remuzzi G (2003) Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 63(6):2254–2261PubMedCrossRefGoogle Scholar
  128. 128.
    Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A–replacement therapy in Fabry’s disease. N Engl J Med 345(1):9–16PubMedCrossRefGoogle Scholar
  129. 129.
    Schiffmann R, Kopp JB, Austin HA III, Sabnis S, Moore DF, Weibel T et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21):2743–2749PubMedCrossRefGoogle Scholar
  130. 130.
    Germain D, Waldek S, Banikazemi M, Bushinsky D, Charrow J, Lee P et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18(5):1547–1557PubMedCrossRefGoogle Scholar
  131. 131.
    Wilcox WR, Banikazemi M, Guffon N, Waldek S, Lee P, Linthorst GE et al (2004) Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am J Hum Genet 75(1):65–74PubMedCrossRefGoogle Scholar
  132. 132.
    Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T et al (2002) Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 33(2):525–531PubMedCrossRefGoogle Scholar
  133. 133.
    Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H (2004) Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 251(5):564–570PubMedCrossRefGoogle Scholar
  134. 134.
    Hughes DA, Mehta AB (2005) Vascular complications of Fabry disease: enzyme replacement and other therapies. Acta Paediatr Suppl 94(447):28–33, discussion 9–10PubMedCrossRefGoogle Scholar
  135. 135.
    Elliott PM, Kindler H, Shah JS, Sachdev B, Rimoldi OE, Thaman R et al (2006) Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 92(3):357–360PubMedCrossRefGoogle Scholar
  136. 136.
    Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M et al (2003) Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138(4):338–346PubMedGoogle Scholar
  137. 137.
    Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R et al (2008) Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab 95(3):163–168PubMedCrossRefGoogle Scholar
  138. 138.
    Kaneski CR, Moore DF, Ries M, Zirzow GC, Schiffmann R (2006) Myeloperoxidase predicts risk of vasculopathic events in hemizygous males with Fabry disease. Neurology 67(11):2045–2047PubMedCrossRefGoogle Scholar
  139. 139.
    Warnock DG, Daina E, Remuzzi G et al (2010) Enzyme replacement therapy and Fabry nephropathy. Clin J Am Soc Nephrol 5:371–378Google Scholar
  140. 140.
    Ruggenenti P, Schieppati A, Remuzzi G (2001) Progression, remission, regression of chronic renal diseases. Lancet 357(9268):1601–1608PubMedCrossRefGoogle Scholar
  141. 141.
    Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J et al (2005) The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 165(8):947–953PubMedCrossRefGoogle Scholar
  142. 142.
    Ruggenenti P, Perticucci E, Cravedi P, Gambara V, Costantini M, Sharma SK et al (2008) Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol 19(6):1213–1224PubMedCrossRefGoogle Scholar
  143. 143.
    Tahir H, Jackson LL, Warnock DG (2007) Antiproteinuric therapy and Fabry nephropathy: Sustained reduction in proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J Am Soc Nephrol 18:2609–2617PubMedCrossRefGoogle Scholar
  144. 144.
    Banikazemi M, Bultas J, Waldek S, Wilcox WR, Whitley CB, McDonald M et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146(2):77–86PubMedGoogle Scholar
  145. 145.
    Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C (2006) Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int 69(7):1216–1221PubMedCrossRefGoogle Scholar
  146. 146.
    Schiffmann R, Askari H, Timmons M, Robinson C, Benko W, Brady R et al (2007) Weekly enzyme replacement therapy may slow decline of renal function in Fabry patients who are on long-term biweekly dosing. J Am Soc Nephrol 18(5):1576–1583PubMedCrossRefGoogle Scholar
  147. 147.
    Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO (2006) Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant 21(2):345–354PubMedCrossRefGoogle Scholar
  148. 148.
    Warnock DG (2007) The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study (NCT00446862) 2007 [updated March 14, 2007; cited 2007 September 9]. Available from http://www.clinicaltrials.gov/ct/search;jsessionid=87169CD1104ADB522E4B53168DEA01DD?term=NCT00446862&submit=Search
  149. 149.
    Warnock DG, Daina E, Remuzzi G, West M (2010) Enzyme replacement therapy and Fabry nephropathy. Clin J Am Soc Nephrol 5:371–378PubMedCrossRefGoogle Scholar
  150. 150.
    Consortium CFR (2009) Canadian Fabry Disease Initiative (CFDI) Enzyme Replacement Therapy (ERT) Study (NCT00455104) 2009 [cited 2009 September 16]. Available from http://clinicaltrials.gov/ct2/show/NCT00455104?term=west+fabry&rank=1
  151. 151.
    Levey AS (2002) Clinical practice. Nondiabetic kidney disease. N Engl J Med 347(19):1505–1511PubMedCrossRefGoogle Scholar
  152. 152.
    Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345(12):861–869PubMedCrossRefGoogle Scholar
  153. 153.
    Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12):851–860PubMedCrossRefGoogle Scholar
  154. 154.
    Hofstetter TH (2001) Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 345(12):910–912CrossRefGoogle Scholar
  155. 155.
    The ESCAPE Trial Group (2009) Strict blood-pressure control and progression of renal failure in children. N Engl J Med 361(17):1639–1650CrossRefGoogle Scholar
  156. 156.
    Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P et al (2007) Progression risk, urinary protein excretion, and treatment effects of Angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 18(6):1959–1965PubMedCrossRefGoogle Scholar
  157. 157.
    de Zeeuw D (2007) Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin Nephrol 27(2):172–181PubMedCrossRefGoogle Scholar
  158. 158.
    Eng CM, Germain DP, Banikazemi M, Warnock DG, Wanner C, Hopkin RJ et al (2006) Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 8(9):539–548PubMedCrossRefGoogle Scholar
  159. 159.
    Jain G, Campbell RC, Warnock DG (2009) Mineralocorticoid receptor blockers and chronic kidney disease. Clin J Am Soc Nephrol 4:1685–1691PubMedCrossRefGoogle Scholar
  160. 160.
    Fervenza FC, Torra R, Warnock DG (2008) Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease. Biologics 2(4):1–22Google Scholar

Copyright information

© Springer Netherlands 2010

Authors and Affiliations

  • David G. Warnock
    • 1
    Email author
  • Carmen Valbuena
    • 2
  • Michael West
    • 3
  • João Paulo Oliveira
    • 2
  1. 1.Division of Nephrology, Department of MedicineUniversity of AlabamaBirminghamUSA
  2. 2.Departments of Pathology, Medicine and Human Genetics, Faculty of MedicineHospital São JoãoPortoPortugal
  3. 3.Department of MedicineDalhousie UniversityHalifaxCanada

Personalised recommendations